The challenges of measuring dementia

Oxford Brain Diagnostic’s Dr Steven Chance explains the importance of early detection of dementia for treatment and research, and why new measurements of neurodegeneration are needed.

Despite trial miss, Novartis still believes in Entresto for ...

Novartis looks set to repurpose cancer drug in MS after tria...

Novartis has announced data supporting a cancer drug it acquired from GlaxoSmithKline and Genmab in a new use in multiple sclerosis, with plans for regulatory filings later this year.

AbbVie axes multi-billion cancer flop Rova-T after another t...

AbbVie has axed its troubled lung cancer drug Rova-T, after another trial failure from the drug that is turning out to be an expensive flop, costing almost $10 billion so far.

Could phase 3 trial win save AZ's troubled Lupus drug?

AstraZeneca has been on a hot streak of trial successes recently, with the latest win being in a late-stage study for a potential lupus drug that looked dead and buried after a major trial

GSK takes option to license hepatitis B RNA drugs from Ionis

GlaxoSmithKline has taken an option to license Ionis’ antisense medicines for people with chronic hepatitis B virus infection after supportive phase 2 trial results.